Fayette Lucie, Brendel Karl, Mentré France
Université Paris Cité et Université Sorbonne Paris Nord, IAME, Inserm, F-75018, Paris, France.
Pharmacometrics, Ipsen Innovation, Les Ulis, France.
J Pharmacokinet Pharmacodyn. 2025 Jul 14;52(4):38. doi: 10.1007/s10928-025-09987-2.
This work focuses on design of experiments for Pharmacokinetic (PK) and Pharmacodynamic (PD) studies. Non-Linear Mixed Effects Models (NLMEM) modelling allows the identification and quantification of covariates that explain inter-individual variability (IIV). The Fisher Information Matrix (FIM), computed by linearization, has already been used to predict uncertainty on covariate parameters and power of test to detect statistical significance. A covariate effect is deemed statistically significant if it is different from 0 according to a Wald comparison test and clinically relevant if the ratio of change it causes in the parameter is relevant according to a test inspired by the two one-sided tests (TOST) as in bioequivalence studies. FIM calculation was extended by computing its expectation on the joint distribution of the covariates, discrete and continuous. Three methods were proposed: using a provided sample of covariate vectors, simulating covariate vectors, based on provided independent distributions or on estimated copulas. Thereafter, CI of ratios, power of tests and number of subjects needed to achieve desired confidence were derived. Methods were implemented in a working version of the R package PFIM6.1. A simulation study was conducted under various scenarios, including different sample sizes, sampling points, and IIV. Overall, uncertainty on covariate effects and power of tests were accurately predicted. The method was applied to a population PK model of the drug cabozantinib including 27 covariate relationships. Despite numerous relationships, limited representation of certain covariates, FIM correctly predicted uncertainty, and is therefore suitable for rapidly computing number of subjects needed to achieve given powers.
这项工作聚焦于药代动力学(PK)和药效动力学(PD)研究的实验设计。非线性混合效应模型(NLMEM)建模能够识别和量化解释个体间变异性(IIV)的协变量。通过线性化计算得到的费舍尔信息矩阵(FIM)已被用于预测协变量参数的不确定性以及检测统计显著性的检验效能。根据 Wald 比较检验,如果协变量效应与 0 不同,则认为其具有统计学显著性;如果根据生物等效性研究中受双单侧检验(TOST)启发的检验,其引起的参数变化比率具有相关性,则认为其具有临床相关性。通过计算 FIM 在离散和连续协变量联合分布上的期望,扩展了 FIM 的计算。提出了三种方法:使用提供的协变量向量样本、基于提供的独立分布或估计的 copula 模拟协变量向量。此后,推导了比率的置信区间、检验效能以及达到所需置信度所需的受试者数量。这些方法在 R 包 PFIM6.1 的工作版本中得以实现。在各种场景下进行了模拟研究,包括不同的样本量、采样点和个体间变异性。总体而言,协变量效应的不确定性和检验效能得到了准确预测。该方法应用于包含 27 个协变量关系的卡博替尼药物群体 PK 模型。尽管存在众多关系且某些协变量的表示有限,但 FIM 正确地预测了不确定性,因此适用于快速计算达到给定效能所需的受试者数量。